Glenmark begins human trials of GBR 830 to treat autoimmune diseases
Glenmark Pharmaceuticals' Swiss subsidiary has announced that its new monoclonal antibody GBR 830 is entering human trials for the treatment of autoimmune diseases.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | Pharmaceuticals